Literature DB >> 9920840

Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner.

L Lorand1, P T Velasco, S N Murthy, P Lefebvre, D Green.   

Abstract

Without a prior history of hemorrhagic disease, a 62-year-old man suffered recurrent episodes of bleeding. Solubility of the patient's clot in 5 mol/L urea indicated a problem with fibrin stabilization. The transamidase activity potential of factor XIII, measured by the incorporation of radioactive putrescine into N,N-dimethylcasein as test substrate, was 62% of control, close to the normal range of values. Examination of the patient's clot from recalcified plasma by sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that essentially none of the alpha chains and only about two thirds of the gamma chains of fibrin became cross-linked under conditions where both were fully cross-linked in the controls. An antibody to factor XIII was isolated which, although recognizing the recombinant rA2 subunits, as well as the virgin A2B2 plasma ensemble, showed a 100-fold greater affinity for the thrombin-activated rA2' and A2'B2 forms of the zymogen, suggesting that the latter would be its main target during coagulation. Furthermore, the patient's IgG has an ability, never seen before, for inducing an enzymatically active configuration in the thrombin-activated zymogen in the absence of Ca2+.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920840

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

Review 1.  Acquired FXIII inhibitors: a systematic review.

Authors:  Massimo Franchini; Francesco Frattini; Silvia Crestani; Carlo Bonfanti
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

2.  Influence of a natural and a synthetic inhibitor of factor XIIIa on fibrin clot rheology.

Authors:  E A Ryan; L F Mockros; A M Stern; L Lorand
Journal:  Biophys J       Date:  1999-11       Impact factor: 4.033

3.  Immunoproteomic Identification of Noncarbohydrate Antigens Eliciting Graft-Specific Adaptive Immune Responses in Patients with Bovine Pericardial Bioprosthetic Heart Valves.

Authors:  Katherine V Gates; Qi Xing; Leigh G Griffiths
Journal:  Proteomics Clin Appl       Date:  2018-12-19       Impact factor: 3.494

4.  Structure-Based Design of FXIIIa-Blockers: Addressing a Transient Hydrophobic Pocket in the Active Site of FXIIIa.

Authors:  Martin Stieler; Christian Büchold; Marisa Schmitt; Andreas Heine; Martin Hils; Ralf Pasternack; Gerhard Klebe
Journal:  ChemMedChem       Date:  2020-04-07       Impact factor: 3.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.